NuMedii, Inc., has been pioneering the use of Big Data, Artificial Intelligence (AI) and systems biology to accelerate the discovery of precision therapies to address high unmet medical needs. As a next-generation biopharma company, NuMedii has built a powerful technology, AIDD (Artificial Intelligence for Drug Discovery), originally developed at Stanford University, that harnesses Big Data and AI to rapidly discover connections between drugs and diseases at a systems level. NuMedii has active R&D collaborations with several global pharmaceutical and biotech companies and patient-centric organizations to create pipeline and new products in multiple therapeutic areas including inflammation, oncology, and rare diseases. Headquartered in Palo Alto, California, the company's investors include Claremont Creek Ventures and Lightspeed Venture Partners.
Enormous amounts of genomic, molecular and other biomedical data and knowledge pertaining to diseases and the behavior of drugs in various model systems are being generated and continue to expand exponentially. The key challenge is efficiently extracting meaning from these vast knowledge and data stores in a way that uncovers new therapeutic options for patients, particularly those who are diagnosed with cancer or rare diseases.
As a next-generation biopharma company, NuMedii has built a powerful technology, AIDD (Artificial Intelligence for Drug Discovery) that harnesses Big Data and AI to rapidly discover connections between drugs and diseases at a systems level. The company has efficiently extracted information from a vast array of disparate data stores to create a structured, proprietary data resource spanning hundreds of diseases and thousands of compounds. Their proprietary AI and machine learning algorithms enable them to extend well beyond conventional 'target-centric' drug discovery approaches by facilitating the exploration of favorable 'poly-pharmacology' profiles that can potentially improve therapeutic efficacy by modulating effects on multiple disease pathways.
An estimated 90% of conventional and blockbuster medicines only work for 30-50% of patients and account for 30% of acute hospital admissions caused by side effects and adverse events. This lack of efficacy could be attributed to differences in individual patients and their response to therapies. A deeper understanding of the complexity of disease manifestation at the molecular and clinical levels will enable developers to better understand the networks involved in these diseases and identify subsets of patients in whom specific treatments may be more effective.
Therefore, NuMedii' AIDD technology can help with myriad aspects of drug discovery including identifying patient subgroups, new therapeutic options (including combinations) and biomarkers. The company' aim is to improve patient outcomes, quickly eliminate unlikely development paths, and increase the product pipeline and speed-to-market for efficacious new therapies for a variety of diseases. Not only do they help partners with their discovery needs, but NuMedii is also building its own pipeline in rare inflammatory diseases and rare oncology indications.